Increase of Prokineticin‐2 in Serum of Patients with Parkinson's Disease
Tommaso Schirinzi, Daniela Maftei, Massimo Pieri, Sergio Bernardini, Nicola Biagio Mercuri, Roberta Lattanzi, Cinzia Severini
Abstract
Prokineticin-2 (PK2) is a chemokine-like peptide abundantly expressed in the central nervous system (CNS), involved in multiple physiological and pathological conditions, which acts as an insult-inducible endangering mediator contributing to cellular defence.1 Of relevance, PK2 is highly induced during early phases of dopaminergic degeneration in Parkinson’s disease (PD), activating a neuroprotective response by the PGC-1αmediated restoration of mitochondrial function
Topics & Concepts
MedicineClassicsLibrary scienceArtComputer scienceParkinson's Disease Mechanisms and TreatmentsHearing, Cochlea, Tinnitus, GeneticsCellular transport and secretion